In 2020, the COVID-19 outbreak exposed a hard truth: the global healthcare system was largely unprepared. Hospitals were overwhelmed, treatment protocols were evolving in real time, and clinicians worldwide were urgently searching for supportive interventions that could improve patient outcomes.

During this period, researchers began examining the role of nutrition and immune support, including microalgae supplementation, as a complementary strategy alongside standard medical care.

A Clinical Study on Spirulina and COVID-19 Patients

Between June 2021 and February 2022, researchers at Tehran University of Medical Sciences conducted a clinical study to evaluate the effects of Spirulina supplementation in hospitalized COVID-19 patients.

The goal was not to replace conventional treatment, but to assess whether Spirulina could support recovery, immune response, and overall outcomes when used in conjunction with standard COVID-19 care.

Study Design and Patient Selection Criteria

The research involved 189 COVID-19 patients, randomly divided into two groups.

Patients were excluded if they:

• Had severe underlying conditions such as cancer, liver dysfunction, or arthritis
• Were pregnant or breastfeeding
• Were taking
• immunosuppressive medications

Group Breakdown

• Spirulina Group: Received 15.2 g of Spirulina daily, in addition to standard COVID-19 treatment
• Control Group: Received standard COVID-19 treatment alone

This randomized approach allowed researchers to compare outcomes between the two groups with minimal bias.

Key Outcomes Observed After Just 7 Days

The results were notable.

After 7 days:

• 15 deaths occurred in the control group
• Zero deaths occurred in the Spirulina group

In addition to mortality outcomes, physicians evaluated symptoms such as:

• Shortness of breath
• Fever and fatigue
• Cough and sore throat
• Headache
• Oxygen saturation stability

Faster Recovery and Higher Discharge Rates

Among non-ICU patients:

• 7% of patients in the Spirulina group were cleared for hospital discharge within 7 days
• Only 39.1% of patients in the control group were cleared for discharge in the same timeframe

Further analysis showed that patients receiving Spirulina were:

• 6 times more likely to be discharged within 7 days
• Experiencing faster symptom reduction and clinical improvement

Immune and Inflammatory Markers Improved With Spirulina

Beyond discharge rates, the study identified several additional benefits linked to Spirulina supplementation:

• Lower mortality risk

• Non-ICU patients were 87% less likely to die
• ICU patients were 84% less likely to die, compared to the control group

• Reduced inflammation
  Blood analysis showed significant reductions in markers associated with:

• Severe inflammation
• Respiratory distress
• Lung damage and organ failure

• Enhanced immune response
  Spirulina improved immune function by:

• Boosting natural killer (NK) cell activity
• Increasing interferon-γ (IFN-γ) secretion, a key antiviral immune signal

Why This Matters for BIOSUPERFOOD and Immune Support

The Spirulina used in this research was Spirulina platensis, one of the four bioavailable microalgae included in the BIOSUPERFOOD blend.

These microalgae were selected after:

• 15+ years of research
• Testing hundreds of algae strains
• Evaluating thousands of nutrient combinations

The final formulation was designed to work synergistically, supporting cellular energy, immune function, and recovery.

For over 20 years, BIOSUPERFOOD has been used worldwide to support:

• Immune resilience
• Cellular nutrition
• Recovery during physical stress

Try BIOSUPERFOOD for Immune & Cellular Support

If you want to explore whole-food microalgae nutrition as part of a proactive health strategy, you can learn more here:

https://bioage.com/product-category/biosuperfood/
(F2k is recommended for first-time users.)